𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacologic approaches to the treatment of Huntington's disease

✍ Scribed by Charles S. Venuto; Andrew McGarry; Qing Ma; Karl Kieburtz

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
149 KB
Volume
27
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Huntington's disease (HD) is an inherited, progressive neurodegenerative disorder characterized by chorea, cognitive impairment, and behavioral disturbances. Despite advances in diagnosis and improved understanding of HD, treatment remains difficult due to challenging symptoms and a paucity of approved therapeutic interventions. Nonpharmacologic and pharmacologic strategies have been evaluated; regarding the latter, over 80 agents of various classes have been investigated in clinical trials or examined in case reports. Symptomatic treatment, however, is generally confined to antidopaminergic agents for motor dysfunction and antidepressants for mood disorders, while treatment for cognitive dysfunction remains vacant. Several different mechanisms to modify symptoms and disease progression have been targeted in clinical trials. This article reviews some of the more common pharmacologic treatments used for HD, discusses data regarding suboptimal agents that have been tested, and surveys treatments under investigation. Β© 2011 Movement Disorder Society

πŸ“œ SIMILAR VOLUMES

Treatment of the symptoms of Huntington'
Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
✍ Livia Brusa; Antonio Orlacchio; Vincenzo Moschella; Cesare Iani; Giorgio Bernard πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 438 KB

## Abstract Aripiprazole (AP), a dopamine (DA) D~2~ receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on ch

The current clinical management of Hunti
The current clinical management of Huntington's disease
✍ Wendy Phillips; Kathleen M. Shannon; Roger A. Barker πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 225 KB

## Abstract Huntington's disease is a neurodegenerative condition, characterized by movement disorders, cognitive decline, and psychiatric disturbance. We review the pharmacological management of the various movement disorders associated with the disease, the cognitive decline and the commonly enco

Perianal fistulae in Crohn's Disease: Cu
Perianal fistulae in Crohn's Disease: Current and future approaches to treatment
✍ Hussila Keshaw; Keen S. Foong; Alastair Forbes; Richard M. Day πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 128 KB πŸ‘ 2 views

Perianal fistulae are common in Crohn's disease but rarely heal without treatment. The main aim of treatment is to effectively close the fistula without affecting sphincter integrity and continence. Traditional surgical and medical approaches are not without their limitations and may result in eithe